Abstract：
Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5-year survival of < 7%, despite the addition of immunotherapy to first-line chemotherapy. Specific tumor biomarkers, such as delta-like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious, novel immunomodulating targeted treatments like bispecific T-cell engaging monoclonal antibodies (tarlatamab) and chemotherapy with PARP inhibitors. However, obtaining a tissue biopsy sample can be challenging in SCLC. Circulating tumor cells (CTCs) have the potential to provide molecular insights into a patient\'s cancer through a \"simple\" blood test. CTCs have been studied for their prognostic ability in SCLC; however, their value in guiding treatment decisions is yet to be elucidated. This review explores novel and promising targeted therapies in SCLC, summarizes current knowledge of CTCs in SCLC, and discusses how CTCs can be utilized for precision medicine.
摘要：
小细胞肺癌（SCLC）是一种高度侵袭性的癌症，5年生存率<7％。尽管在一线化疗中加入了免疫治疗。特异性肿瘤生物标志物，如δ样配体3(DLL3)和schlafen11(SLFN11)，可以选择更有效的，新型免疫调节靶向治疗如双特异性T细胞结合单克隆抗体(tarlatamab)和PARP抑制剂化疗.然而,在SCLC中获得组织活检样本可能是具有挑战性的。循环肿瘤细胞（CTC）有可能通过“简单”的血液测试提供对患者癌症的分子见解。已经研究了CTC在SCLC中的预后能力；然而，它们在指导治疗决策方面的价值尚待阐明。这篇综述探讨了SCLC中新颖且有前途的靶向治疗方法，总结了SCLC中CTC的最新知识，并讨论了CTC如何用于精准医疗。
